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Abstract
Introduction
• GDM rates are rising in the United States, but there are no current best 
practice recommendations for treatment beyond initial diet/exercise 
modifications (SMFM, 2018).
• As of 2009, 7% of pregnancies were complicated by diabetes, with GDM 
representing 86% of that population (Caughey & Turrentine, 2018).
• Persistent hyperglycemia will result in complications such as neonatal 
macrosomia or hypoglycemia (Poomalar, 2015). 
• Historically, insulin therapy was thought to be second-line treatment if 
diet/exercise failed to achieve euglycemic control (Poomalar, 2015)
• Since 2007, in the United States, glyburide has become the most frequently 
prescribed medication for GDM management beyond diet/exercise 
modifications (Corcoy, 2018).
• Outside the United States, particularly in New Zealand, GDM treatment 
with metformin is becoming increasingly popular (Corcoy, Balsells, 
Garcia-Patterson, Shmueli, & Hadar, 2018).
• Insulin delivery can either be via subcutaneous multiple daily injections 








In patients with GDM, is there a difference in rates of macrosomia and neonatal 
hypoglycemia when comparing metformin, glyburide, insulin via MDI and insulin via 
CSII?
• Glyburide: 
– Overall, lack of statistically significant data.
– However, there are multiple reviews illustrating higher rates of macrosomia and 
neonatal hypoglycemia associated with GDM treated glyburide vs insulin or 
metformin.
– Glyburide crosses placental barrier and reaches concentration of up to 70% of 
maternal concentrations (SMFM, 2018).
– Lack of studies assessing long-term effects of in-utero glyburide use.
• Metformin: 
– Overall, lack of  statistically significant data.
– Some evidence of lower rates of neonatal hypoglycemia and macrosomia when 
compared to both insulin and glyburide. 
• Insulin via MDI/CSII: 
– Overall, lack of statistically significant data, as well as studies assessing GDM 
management with CSII.
– No difference in rates of macrosomia or neonatal glycemia between MDI/CSII.
In patients with GDM, will taking metformin, glyburide, insulin via MDI, or insulin via 
CSII yield safer and more efficacious results?
• Both metformin and glyburide cross placental barriers.
– Serum cord concentration of metformin is equivalent to maternal serum 
concentrations of metformin (SMFM, 2018).
– Serum cord concentrations of glyburide are 70% of maternal concentrations (SMFM, 
2018)
• 2 year follow-up of children from GDM mothers treated with metformin had less 
intraabdominal fat and more subcutaneous fat causing question if metformin use in-
utero changes neonatal fat distribution changes (SMFM, 2018).
• Higher rates of supplemental insulin needed in metformin managed GDM treatment 
groups.
• Overall lack of studies assessing long-term effects of in-utero metformin or glyburide 
use.
• Lack of statistically significant data assessing safety and efficacy of CSII use for GDM 
management.
• Lack of studies comparing GDM treated with MDI versus CSII.
Gestational diabetes mellitus (GDM) is a known potential complication that 
can occur during pregnancy. Unmanaged GDM can result in maternal 
hyperglycemia, which can cause increased neonatal complications, two of 
which are macrosomia and neonatal hypoglycemia. To prevent maternal 
hyperglycemia, treatment of GDM typically begins with dietary changes, 
home glucose monitoring, increased exercise patterns and other lifestyle 
modifications. However, if maternal hyperglycemia persists after two weeks 
of maternal lifestyle modifications, there are not current best practice 
guidelines established for the treatment of GDM. Historically, subcutaneous 
multiple daily dosed insulin (MDI) has been the gold standard for treatment 
after lifestyle modification. However, in more recent years oral 
antihyperglycemic medications, glyburide and metformin, have seen 
increased use for the treatment of GDM. Additionally, with advancing 
technology and the development of continuous subcutaneous insulin 
infusion (CSII), there is discussion regarding which insulin delivery method 
will achieve more consistent rates of euglycemia to help reduce rates of 
neonatal hypoglycemia and macrosomia. This scholarly literature review 
will provide a general overview of GDM, compare treatment modalities 
(subcutaneous multiple daily dosages of insulin, continuous subcutaneous 
insulin infusion, metformin and glyburide) of GDM in terms of rates of 
neonatal hypoglycemia and macrosomia, and compare the safety of 
differing treatment modalities. 
Keywords:  Gestational diabetes mellitus, macrosomia, neonatal 
hyperglycemia, glyburide, metformin, insulin, continuous subcutaneous 
insulin infusion (CSII)
• In patients with GDM, is there a difference in rates of macrosomia and 
neonatal hypoglycemia when comparing metformin, glyburide, insulin via 
MDI, and insulin via CSII?
• In patients with GDM, will taking metformin, glyburide, insulin via MDI or 
insulin via CSII, yield safer and more efficacious results?
• MDI vs CSII:
– A 2004  meta-analysis of six small randomized control trials failed to demonstrate 
better glycemic control or improved fetal outcomes with a CSII compared to 
insulin delivery via MDI (Kesavadev, 2014).
– A review of glycemic control of DM1 in pregnancy found no difference between 
MDI and CSII regarding glycemic control (Castorino, Paband, Zisser, & 
Jovanovic, 2012)
– A 2016 Cochrane review found there to be insufficient evidence to conclude 
whether CSII or MDI would produce better outcomes for diabetes management in 
pregnancy (Farrar, Tuffnell, West, J. & West, HM., 2016)
– Safety: 
• The American Association of Clinical Endocrinologist’s Consensus Panel on 
insulin pump management recommended CSII for glycemic control in 
pregnancies complicated by DM2 or GDM if large amounts of insulin are 
required (Kesavadev, 2016).
• Castorino’s 2011 review recommended women be competent pump users prior 
to conception if they consider CSII use in pregnancy. 
• Glyburide vs Insulin:
– Out of 809 women included in a multi-institutional randomized control trial by 
Senat et al., outcomes including macrosomia or neonatal hypoglycemia occurred 
in 23.4% of infants born to insulin treated GDM vs 27.6% of infants born to 
glyburide treated GDM (Coustan and Barbour, 2018).
– Reviews comparing insulin to glyburide showed higher rates of macrosomia and 
neonatal hypoglycemia in GDM pregnancies treated with glyburide (SMFM, 
2018 and Malek & Davis, 2016).
– GDM pregnancies treated with glyburide or insulin failed to show statistically 
significant differences in rates of macrosomia or neonatal hypoglycemia (p= 0.84) 
(Mirzamoradi, Heidar, Faalpoor, Naeiji, & Jamali, 2014).
– Safety: 
• Glyburide crosses the placental barrier, whereas insulin does not. Serum 
glyburide concentrations in the umbilical cord have been found to be 70% of 
maternal levels (SMFM, 2018). 
• Metformin vs Insulin: 
– Despite a lack in statistically significant data, metformin has shown lower rates of 
macrosomia and neonatal hypoglycemia in multiple studies when compared to 
insulin treated GDM (Corcoy et al., 2018), (SMFM, 2018), (Poomalar, 2015), (Su
& Wang, 2014), and (Kitwitee et al., 2015)
– Safety: 
• Metformin as shown higher rates of preterm births, but less maternal weight 
gain (SMFM, 2018).
• Metformin crosses the placental barrier and  reaches a fetal concentration rate 
similar to the maternal concentration rates (SMFM, 2018).
• 2-year old children, whom were exposed to metformin in utero due to the 
treatment of GDM, were found to have similar body fat but more 
subcutaneous body fat compared to intraabdominal body fat when compared to 
insulin treated GDM 2-year old's (SMFM, 2018).
• Glyburide vs Metformin: 
– Metformin, compared to glyburide, showed lower risk of neonatal hypoglycemia 
and macrosomia, and had similar rates of preterm births (SMFM, 2018) and 
(Corcoy et al, 2018).
– However, a 2017 Cochrane review found no difference in rates of neonatal 
hypoglycemia or macrosomia (Brown et al., 2017)
– Safety: 
• Both glyburide and metformin cross placental barriers and have been found in 
umbilical cord serum concentrations (SMFM, 2018).
• Metformin has a higher rate of supplemental insulin use compared to 
glyburide (Corcoy et al, 2018).
• Overall broad conclusion: more research needs to be conducted evaluating the 
management of GDM beyond diet/exercise modifications.
• CSII may be an option for women who have prior experience with a  pump, history of 
GDM, or for those highly motivated to learn how to use a pump.
– Pump therapy education is a deterrent to the use of CSII for those newly diagnosed 
with GDM.
– MDI is faster to learn and may help achieve euglycemia more quickly than GSII .
• Both Metformin and Glyburide cross the placental barrier
– Current research has shown lower rates of neonatal hypoglycemia and macrosomia 
with metformin, although there is a lack of statistically significant data. 
– Minimal research assessing long-term effects of glyburide or metformin on fetus, 
infant, or child.
• 2018 ACOG guidelines continue to recommend insulin as first-line therapy for GDM if 
diet/exercise fail to control hyperglycemia (Caughey & Turrentine, 2018).
– ACOG further recommends that if insulin is not appropriate for the patient, or is too 
costly for the patient, metformin should be considered the next option for treatment 
(Caughey & Turrentine, 2018).
• Ultimately, treatment option, beyond diet/exercise modifications, needs to be a shared 
decision between patient and their provider.
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Statement of the Problem
Beyond diet/exercise modifications, there are no best practice treatment 
recommendations for GDM. Therefore, it is necessary to compare rates of 
neonatal macrosomia, neonatal hypoglycemia, and safety and efficacy of 
GDM treatment modalities including: oral antihyperglycemics (metformin and 
glyburide), subcutaneous MDI, and CSII. 
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